Hangzhou XinZeyuan Medical Completes Over RMB 100 Million Series B Financing to Advance Upstream Innovation in Minimally Invasive Surgical Devices

VCBeat has learned that recently, a supply chain platform enterprise for MicroPort medical devicesHangzhou Xinzeyuan Precision Products Co., Ltd. (hereinafter referred to as "Xinze Yuan")Announced the successful completion of a Series B financing round exceeding RMB 100 million. This round was led byQiming Venture PartnersLead investor,Paradise Silicon ValleyCo-investment,Dianshi CapitalServing as the exclusive financial advisor. The new round of financing will be primarily used for the research and development of core upstream technologies, the construction of production bases, and other initiatives, with the aim of building a world-class supply chain platform for minimally invasive medical devices.

Founded in 2015 and headquartered in Hangzhou, HANGZHOU XINZEYUAN PRECISION PRODUCTS CO.,LTD has deeply cultivated the minimally invasive supply chain sector, supporting the growth of downstream enterprises in China. It has established a full-link supply platform centered on endoscopes and endoscopic consumables. The company’s portfolio covers over 30,000 types of minimally invasive medical components and more than 3,600 assemblies, offering end-to-end service capabilities from “concept design” to “mass production and market launch.”

The terminal market size for minimally invasive medical devices exceeds RMB 45 billion, and the situation where the industry chain was heavily dependent on imported products is being reversed. In the endoscopy field, sectors such as reusable flexible endoscopes, reusable rigid endoscopes, and single-use endoscopes are flourishing, challenging the dominant position of overseas enterprises. In the field of endoscopic consumables, intensive centralized procurement is driving further independent innovation and promoting more refined division of labor within the industry chain. The rise of downstream domestic brands has created greater product demand and higher technical requirements for the supply chain, bringing historic opportunities to upstream enterprises.

Xinze Yuan is a Chinese supplier that pioneered full-chain supply capabilities for minimally invasive medical devices in China, serving as a core player in independent innovation within the supply chain. In the field of flexible endoscope bodies, long monopolized by international giants, Xinze Yuan has overcome precision manufacturing challenges for over 300 core components, delivering products that rival global brands in both appearance and performance. Leveraging its advantage in in-house production of core components and refined manufacturing processes developed over time, the company collaborates closely with leading downstream brands to build a platform centered on full-chain supply of minimally invasive medical devices. It serves a broad range of medical brands through four key business segments: rigid endoscopes, flexible endoscopes, endoscopic surgical instruments, and minimally invasive surgical instruments. The company has gained recognition from more than 400 device customers, including Mindray Medical, and its products are exported to over 20 countries and regions worldwide.

Wang Qiurong, Chairman of Xinzeyuanstated: “We extend our gratitude to Qiming Venture Partners and Paradise Silicon Valley for their trust and support. Over the past decade, Xinzeyuan’s continuous R&D efforts and product iterations in the upstream sector of minimally invasive medical devices have earned recognition from numerous clients and industry peers. Looking ahead, Xinzeyuan will continue to advance along its business pathway of ‘one core platform and four business modules,’ serving the field of minimally invasive medicine and delivering value to shareholders and the industry.”

Zhang Ao, Executive Director at Qiming Venture Partnersstated: “We have long focused on investment opportunities within the medical device industry chain. While independent innovation among downstream medical device enterprises is flourishing, the upstream sector is at an inflection point of accelerated development. Over the past decade, alongside the growth of outstanding domestic downstream companies, Xinzeyuan has accumulated profound expertise in manufacturing processes and product understanding, and has continuously innovated its technologies, becoming a minimally invasive medical device supply chain platform enterprise integrating precision machining, polymer materials, structural design, and process engineering capabilities. We will continue to support Xinzeyuan in developing core technologies, serving downstream customers, and contributing to the advancement of China’s medical device industry.”

Bao Xueqing, Managing Partner at Paradise Silicon ValleyStatement: The competitiveness of China’s medical device industry chain in the global market is steadily increasing, driven by accelerated independent innovation and a more clearly defined division of labor within the supply chain. Upstream enterprises with core competencies and advantages are not only able to focus on the research and development of advanced processes and materials, thereby expanding product possibilities, but also leverage economies of scale to achieve high-quality production at low costs, fostering close collaboration across the upstream and downstream sectors. HANGZHOU XINZEYUAN PRECISION PRODUCTS CO.,LTD has already secured a leading position in the upstream segment of the minimally invasive medical device sector, accumulating a substantial base of high-quality clients and orders, and is poised to enter a phase of rapid growth. Paradise Silicon Valley is delighted to partner with Xinzeyuan and support its development. We believe that as Xinzeyuan continues its rapid expansion, it will better empower medical device companies and facilitate the global expansion of China’s medical device industry chain.

Ren Zhong, Founding Partner of Dianshi Capitalstated: “Xinze Yuan is committed to building a world-class, end-to-end supply platform for minimally invasive medical devices. The Dianshi team is honored to have served Xinze Yuan in this round of financing. Throughout the fundraising process, we were impressed by the team’s profound technical expertise and exceptional execution capabilities. We are confident that Xinze Yuan will continue to provide high-quality upstream solutions to healthcare enterprises worldwide. We are dedicated to supporting Xinze Yuan’s growth and contributing to the advancement of the medical device industry.”

Qiming Venture Partners was established in 2006. The firm currently manages 11 US dollar funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming Venture Partners has focused on investing in outstanding early-stage and growth-stage companies in the technology and consumer, healthcare, and other sectors. To date, the firm has invested in more than 530 high-growth innovative enterprises, among which over 200 have been listed on exchanges such as the New York Stock Exchange, NASDAQ, Hong Kong Stock Exchange, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or have exited through mergers and acquisitions. More than 70 of these portfolio companies have become industry-recognized unicorns or super unicorns.

Tiantang Silicon Valley (TTGG), established in 2000, is one of the first fund managers founded in China. Adhering to the business philosophy of “Investors First, Value Investment, and Industry Focus,” it specializes in venture capital investments in three key sectors: intelligent technology, advanced manufacturing, and healthcare. To date, the company and its managed funds have invested in 220 equity projects, among which 50 portfolio companies have been listed on the A-share, Hong Kong Stock Exchange, and U.S. stock markets.

Dianshi Capital is a boutique investment bank with a composite background in strategic consulting, investment and financing, and industry expertise, focusing on the fields of life sciences and hard technology. We provide enterprises with full-process services, including business strategy refinement, capital strategy planning, and business resource matchmaking, serving as a trusted capital partner for companies and achieving multi-party win-win outcomes for investors and entrepreneurs.